1. Home
  2. FOXX vs SNTI Comparison

FOXX vs SNTI Comparison

Compare FOXX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FOXX

Foxx Development Holdings Inc.

HOLD

Current Price

$3.50

Market Cap

35.6M

Sector

N/A

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$1.07

Market Cap

29.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
SNTI
Founded
2017
2016
Country
United States
United States
Employees
25
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.6M
29.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FOXX
SNTI
Price
$3.50
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
3.6M
163.7K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.71
$0.77
52 Week High
$8.70
$2.88

Technical Indicators

Market Signals
Indicator
FOXX
SNTI
Relative Strength Index (RSI) 49.33 57.03
Support Level $2.69 $0.88
Resistance Level $4.88 $1.19
Average True Range (ATR) 0.38 0.06
MACD 0.06 0.01
Stochastic Oscillator 80.29 64.66

Price Performance

Historical Comparison
FOXX
SNTI

About FOXX Foxx Development Holdings Inc.

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: